Clinical significance of ≥ 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients.

ABSTRACT:

Background

PD-L1 expression in tumor cells has been associated with the efficacy of immune checkpoint inhibitors in non-small cell lung cancer (NSCLC). The aim of this study was to explore correlations between smoking, genetic profiles, patient outcomes, and PD-L1 expression in NSCLC.

Methods

PD-L1 expression was evaluated in 241 surgically resected specimens by immunostaining and 50% was set as the cutoff value.

Results

Of the 241 tumors analyzed, a PD-L1 tumor proportion score (TPS) of ≥ 50% was detected in 35 cases (14.5%) and a TPS of < 50% in 206 cases (85.5%). A PD-L1 TPS ≥ 50% was significantly associated with smoking and EGFR wild-type status (P < 0.001 and P = 0.039, respectively). Detailed assessment of smoking variables showed that total smoking duration wa

SUBMITTER: Li W 

PROVIDER: S-EPMC6360219 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature